lung cancer
Conditions
Interventions
1:concurrent chemotherapy consisted of Docetaxel 56 mg/m2 and Cisplatin 56 mg/m2, on day 1 and day 2, repeated every three weeks for a total of six weeks
2:concurrent chemotherapy consisted of Docetaxel 60 mg/m2 and Cisplatin 60 mg/m2, on day 1 and day 2, repeated every three weeks for a total of six weeks
3:concurrent chemotherapy consisted of Docetaxel 64 mg/m2 and Cisplatin 64 mg/m2, on day 1 and day 2, repeated every three weeks for a total of six weeks
Sponsors
Peking University School of Oncology, Beijing Cancer Hospital & Institute
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Histologically or cytologically confirmed unresectable stage IIIA or stage IIIB non-small cell lung; 2. At least 1 bidimensionally or unidimensionally measurable lesion less than 8cm; 3. Age: 18-70 years old, no more than 10% weight loss within past 6 months, life expectancy >12 months and tolerent radiation; 4. No chest RT history and no other treatment for cancer in the last month; 5. The ECOG 0-1; 6. No main organ function disable, Leucocyte>= 4000/uL, a neutrophil count>=1500/uL, PLT >=10000/uL, hemoglobin>=10g/dL, CR=1.5 L and >50% upper limit of normal; 8. Patients shoud understand and sign the Informed consent.
Exclusion criteria
Exclusion criteria: 1. Patients are receiving other anti-cancer therapy, and pregnant and lactating women; 2. Patients with a second primary tumor other than non-melanoma skin cancer or in situ cervical carcinoma; 3. Any chemotherapy contraindications such as active infection, uncontrolled diabetes, prior allergic reaction to docetaxel and other serious disease, for example myocardial infarction. 4. Uncontrolable madman psychopath; 5. Investigator consider inappropriate patients for the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Response rate and toxicity; | — |
Countries
China
Contacts
Public Contactzhu guangying
Outcome results
None listed